Germany's Evotec Gets Takeover Interest From Halozyme [Yahoo! Finance Canada]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance Canada
Most Read from Bloomberg Halozyme said in a statement confirming an earlier report by Bloomberg News that it has submitted a non-binding proposal to acquire Evotec for €11 per share. That would represent a roughly 27% premium to Evotec's closing price on Thursday. Halozyme Chief Executive Officer Helen Torley said in the statement that acquiring Evotec would extend her company's growth into the next decade and beyond. “With increased scale, a deep pipeline, and a diversified offering, we would be a highly attractive strategic partner to the biopharma industry,” she said. Evotec said in a separate statement that would carefully analyze the offer and decide on its next steps. American depositary receipts of Evotec, after rising as much as as much as 19% Thursday, closed up 12% in New York, giving the company a market value of about $1.8 billion. San Diego, California-based Halozyme's shares fell 7.9%, giving it a market value of about $6.9 billion. Shares of Evotec had fallen
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term [Yahoo! Finance]Yahoo! Finance
- Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in DiscussionsPR Newswire
- Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.MarketBeat
- HALO vs. FOLD: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
HALO
Earnings
- 10/31/24 - Beat
HALO
Sec Filings
- 11/12/24 - Form SC
- 10/31/24 - Form 10-Q
- 10/31/24 - Form 8-K
- HALO's page on the SEC website